{"analyses":[{"ciLowerLimit":"1.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.8","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0007","paramType":"Odds Ratio (OR)","paramValue":"2.3","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.5","upperLimit":"84.8","value":"79.1"},{"groupId":"OG001","lowerLimit":"57.2","upperLimit":"71.6","value":"64.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"181"}],"units":"Participants"}],"description":"Defined as percentage of participants achieving RBC-TI for \\>= 56 days during any consecutive 56-day period from Week 1 through Week 24.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"NUMBER","populationDescription":"ITT Population - all randomized participants regardless of whether or not the participant received treatment.","reportingStatus":"POSTED","timeFrame":"Week 1 through Week 24","title":"Percentage of Participants Achieving Red Blood Cell Transfusion Independence (RBC-TI) for ≥ 56 Days (8 Weeks)","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}